Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras

A pharmaceutical composition comprising a cyclic compound represented by formula (1) below or a salt thereof, or a solvate thereof:

• wherein:
• L1 is a single bond, or is —CHM1-, —(CH2)nS(CH2)m—, —(CH2)nS(O)(CH2)m—, or —(CH2)nS(O)2(CH2)m—, wherein n and m are each independently 1 or 2,
• R1 is any of (a1) to (a6) below:
• (a1) R1 is hydrogen, C1-C7 alkyl, C2-C7 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxyC1-C6 alkyl, C1-C6 alkylthioC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C14 aralkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, C1-C6 alkyl, aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl;
• (a2) R1, together with P1, the carbon atom to which R1 is bonded, and the nitrogen atom to which P1 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• (a3) R1, together with Q1 and the carbon atom to which R1 and Q1 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• (a4) R1, together with M1, the carbon atom to which R1 is bonded, and the carbon atom to which M1 is bonded, forms a 3- to 8-membered alicyclic ring;
• (a5) R1, together with R5, forms a divalent group selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C8 cycloalkylene, C6-C10 arylene, —CO—NRA—, —NRA—CO—, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 alkyl, and RA is hydrogen or C1-C6 alkyl;
• or
• (a6) R1, together with R9, forms a divalent group selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C8 cycloalkylene, C6-C10 arylene, —CO—NRB—, —NRB—CO—, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group is optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 alkyl, and RB is hydrogen or C1-C6 alkyl;
• P1, except when R1 and P1 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q1, except when R1 and Q1 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, and
• M1, except when R1 and M1 form a 3- to 8-membered alicyclic ring, is hydrogen or C1-C6 alkyl,
• R2 is any of (b1) to (b4) below:
• (b1) R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or 4- to 7-membered heterocyclyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, and C1-C6 alkylsulfonyl;
• (b2) R2, together with P2, the carbon atom to which R2 is bonded, and the nitrogen atom to which P2 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• (b3) R2, together with Q2 and the carbon atom to which R2 and Q2 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• or
• (b4) R2, together with R11, forms a divalent group selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C8 cycloalkylene, C6-C10 arylene, —CO—NRC—, —NRC—CO—, —C3-C8 alkylene-NRC—, —C3-C8 alkenylene-NRC—, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 alkyl, and RC is hydrogen or C1-C6 alkyl;
• P2, except when R2 and P2 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q2, except when R2 and Q2 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R3 is any of (c1) to (c3) below:
• (c1) R3 is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C14 aralkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of hydroxy and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino);
• (c2) R3, together with P3, the carbon atom to which R3 is bonded, and the nitrogen atom to which P3 is bonded, forms a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more groups selected from the group consisting of C1-C6 alkyl and C1-C6 alkoxy;
• or
• (c3) R3, together with Q3 and the carbon atom to which R3 and Q3 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• P3, except when R3 and P3 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, cyano, C1-C6 alkoxy, and C1-C6 aminoalkyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, and the 4- to 8-membered cyclic amino is optionally substituted with one or more halogen atoms),
• Q3, except when R3 and Q3 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R4 is any of (d1) to (d4) below:
• (d1) R4 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxyC1-C6 alkyl, or C1-C6 carboxyalkyl, each of which is optionally substituted with one or more hydroxy groups;
• (d2) R4, together with P4, the carbon atom to which R4 is bonded, and the nitrogen atom to which P4 is bonded, forms a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more C1-C6 alkyl groups;
• (d3) R4, together with Q4 and the carbon atom to which R4 and Q4 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• or
• (d4) R4, together with P5, forms a divalent group selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C8 cycloalkylene, 3- to 7-membered heterocyclylene, C6-C10 arylene, —CO—NRD—, —NRD—CO—, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 alkyl, and RD is hydrogen or C1-C6 alkyl;
• P4, except when R4 and P4 form a 4- to 7-membered saturated heterocyclic ring, is any of (e1) to (e2) below:
• (e1) P4 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino);
• or
• (e2) P4, together with P5, forms a divalent group selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C8 cycloalkylene, C6-C10 arylene, —CO—NRE—, —NRE—CO—, and a combination of two or more of these, wherein one or more carbon atoms constituting the divalent group are optionally substituted with one or more heteroatoms independently selected from the group consisting of N, O, and S, the divalent group is optionally substituted with one or more groups independently selected from the group consisting of halogen and C1-C6 alkyl, and RE is hydrogen or C1-C6 alkyl;
• Q4, except when R4 and Q4 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R5, except when R1 and R5 form a divalent group, is any of (f1) to (f4) below:
• (f1) R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, C7-C14 aralkyl, C6-C10 aryloxyC1-C6 alkyl, C7-C14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C2-C6 alkenyloxy, C1-C6 haloalkoxy, cyano, and C1-C6 alkylsulfonyl, C2-C6 alkenyl, C3-C8 cycloalkyl, and C1-C6 alkylcarbonyl;
• or
• (f2) R5, together with R8, forms C4-C8 alkylene;
• (f3) R5, together with P5, the carbon atom to which R5 is bonded, and the nitrogen atom to which P5 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• or
• (f4) R5, together with Q5 and the carbon atom to which R5 and Q5 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• P5, except when R5 and P5 form a 4- to 7-membered saturated heterocyclic ring, except when R4 and P5 form a divalent group, and except when P4 and P5 form a divalent group, is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, or C3-C8 cycloalkylC1-C6 alkyl, wherein the C1-C6alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and amino,
• Q5, except when R5 and Q5 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R6 is any of (g1) to (g3) below:
• (g1) R6 is hydrogen or C1-C6 alkyl;
• (g2) R6, together with P6, the carbon atom to which R6 is bonded, and the nitrogen atom to which P6 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• or
• (g3) R6, together with Q6 and the carbon atom to which R6 and Q6 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• P6, except when R6 and P6 form a 4- to 7-membered saturated heterocyclic ring, is C1-C6 alkyl or C3-C8 cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q6, except when R6 and Q6 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R7 is any of (h1) to (h3) below:
• (h1) R7 is C6-C10 aryloxyC1-C6 alkyl, C7-C14 aralkyl, C7-C14 aralkoxyC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, C1-C6 alkylsulfonyl, SFS, and C3-C8 cycloalkyl;
• (h2) R7, together with P7, the carbon atom to which R7 is bonded, and the nitrogen atom to which P7 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• or
• (h3) R7, together with Q7 and the carbon atom to which R7 and Q7 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• P7, except when R7 and P7 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q7, except when R7 and Q7 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R8, except when R5 and R8 form C4-C8 alkylene, is any of (i1) to (i3) below:
• (i1) R8 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxycarbonylC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C6-C10 aryloxyC1-C6 alkyl, C7-C14 aralkyl, C7-C14 aralkoxyC1-C6 alkyl, 5- to 10-membered heteroarylC1-C6 alkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, carboxy, C1-C6alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkoxy, cyano, aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino, each of which is optionally substituted with halogen), 4- to 7-membered heterocycloalkylidene, protected 4- to 7-membered heterocycloalkylidene, 4- to 7-membered heterocyclyl, and protected 4- to 7-membered heterocyclyl;
• (i2) R8, together with P8, the carbon atom to which R8 is bonded, and the nitrogen atom to which P8 is bonded, forms a 4- to 7-membered saturated heterocyclic ring, wherein the 4- to 7-membered saturated heterocyclic ring is optionally condensed with a saturated carbon ring or an aromatic ring, the 4- to 7-membered saturated heterocyclic ring is optionally substituted with one or more halogen atoms, oxo, one or more C1-C6 alkyl groups, C1-C6 haloalkyl, C3-C8 spirocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, 4- to 8-membered cyclic amino (wherein the cyclic amino is optionally substituted with one or more halogen atoms), or OS8, and S8 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkylC1-C6 alkyl, 4- to 7-membered heterocyclyl, C7-C14 aralkyl (wherein the aralkyl is optionally substituted with one or more halogen atoms, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 haloalkoxy), 5- to 10-membered heteroarylC1-C6 alkyl, or C3-C8 cycloalkyl;
• or
• (i3) R8, together with Q8 and the carbon atom to which R8 and Q8 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• P8, except when R8 and P8 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen, C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC2-C6 alkenyl, C3-C8 cycloalkyl, 4- to 7-membered heterocyclyl, 4- to 7-membered heterocyclylC1-C6 alkyl, C6-C10 aryl, C7-C14 aralkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroarylC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q5, except when R8 and Q8 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• M9 is —N(P9)—:
• R9, except when R1 and R9 form a divalent group, is any of (j1) to (j3) below:
• (j1) R9 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxyC1-C6 alkyl, C2-C6 alkenyloxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C7-C14 aralkyl, or 5- to 10-membered heteroarylC1-C6 alkoxyC1-C6 alkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl;
• (j2) R9, together with P9, the carbon atom to which R9 is bonded, and the nitrogen atom to which P9 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• or
• (j3) R9, together with Q9 and the carbon atom to which R9 and Q9 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, each of which is optionally substituted with one or more halogen atoms or one or more C1-C6 alkyl groups;
• P9, except when R9 and P9 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q9, except when R9 and Q9 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl,
• R10 is any of (k1) to (k3) below:
• (k1) R10 is C1-C6 alkyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C6 alkyl, C3-C8 cycloalkoxyC1-C6 alkyl, or C7-C14 aralkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, and C1-C6 alkylsulfonyl;
• (k2) R10, together with P10, the carbon atom to which R10 is bonded, and the nitrogen atom to which P10 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• or
• (k3) R10, together with Q10 and the carbon atom to which R10 and Q10 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• P10, except when R10 and P10 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q10, except when R10 and Q10 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, and
• L11 is a single bond, or is —CHM11-, —(CH2)nS(CH2)m—, —(CH2)nS(O)(CH2)m—, or —(CH2)nS(O)2(CH2)m—, wherein n and m are each independently 1 or 2,
• R11, except when R2 and R11 form a divalent group, is any of (11) to (15) below:
• (l1) R11 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxyC1-C6 alkyl, C7-C14 aralkyl, aminocarbonyl (wherein the amino is —NH2, mono C1-C6 alkylamino, di-C1-C6 alkylamino, N—C1-C6 alkyl-N—C2-C6 alkenylamino, or 4- to 8-membered cyclic amino), or C3-C8 cycloalkyl, each of which is optionally substituted with one or more groups independently selected from the group consisting of halogen, oxo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, 4- to 7-membered heterocyclyl, aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino), and C1-C6 alkylsulfonyl;
• (l2) R11 is a peptide chain containing 1 to 4 amino acid residues;
• (l3) R11, together with P11, the carbon atom to which R11 is bonded, and the nitrogen atom to which P11 is bonded, forms a 4- to 7-membered saturated heterocyclic ring;
• (l4) R11, together with Q11 and the carbon atom to which R11 and Q11 are bonded, forms a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring;
• or
• (l5) R11, together with M1, the carbon atom to which R11 is bonded, and the carbon atom to which M11 is bonded, forms a 3- to 8-membered alicyclic ring;
• P11, except when R11 and P11 form a 4- to 7-membered saturated heterocyclic ring, is hydrogen, C1-C6 alkyl, C3-C8 cycloalkylC1-C6 alkyl, or C7-C14 aralkyl, wherein the C1-C6 alkyl is optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy, and aminocarbonyl (wherein the amino is —NH2, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, or 4- to 8-membered cyclic amino),
• Q11, except when R11 and Q11 form a 3- to 8-membered alicyclic ring or a 4- to 7-membered saturated heterocyclic ring, is hydrogen or C1-C6 alkyl, and
• M11, except when R11 and M11 form a 3- to 8-membered alicyclic ring, is hydrogen, and
• at least three of P1 to P11 are not hydrogen.

A pharmaceutical composition for treatment or prevention of a cell proliferative disease, comprising a cyclic compound selected from the group consisting of:

• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclopentane]-23-carboxamide,
• (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,24,36-octamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[2,8,11,14,18,21,24,30,33,36,39-undecazatetracyclo[37.5.1.04,8.026,30]pentatetracont-42-ene-23,1′-cyclobutane]-17-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclopentane]-23-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclopentane]-23-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-27-[(1R)-1-methoxyethyl]-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-(p-tolylmethyl)spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclopentane]-23-carboxamide,
• (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,36-heptamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-13-propyl-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[24-oxa-2,8,11,14,18,21,30,33,36,39-decazatetracyclo[37.5.1.04,8.026,30]pentatetracont-42-ene-23,1′-cyclobutane]-17-carboxamide,
• (1S,4S,10S,13S,17S,20S,26S,28R,32S,38S,42Z)-20-cyclopentyl-28-ethoxy-13-[(1R)-1-methoxyethyl]-32-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,2,14,18,21,36-heptamethyl-10-[(1S)-1-methylpropyl]-3,9,12,15,19,22,25,31,34,37,45-undecaoxo-38-[[4-(trifluoromethyl)phenyl]methyl]spiro[24-oxa-2,8,11,14,18,21,30,33,36,39-decazatetracyclo[37.5.1.04,8.026,30]pentatetracont-42-ene-23,1′-cyclobutane]-17-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-20-cyclopentyl-12-ethoxy-27-[(1R)-1-methoxyethyl]-8-[2-[3-methoxy-4-(trifluoromethyl)phenyl]ethyl]-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-27-butyl-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-fluoro-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,
• (6'S,9'S,13'S,16'S,22'S,29'S,35'S,40a'S,Z)-16′-((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-N,N,5′,8′,12′,18′,21′,31′-octamethyl-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaoxo-6′-(pentan-3-yl)-13′-propyl-29′-(4-(trifluoromethyl)benzyl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratriacontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclooctatriacontine-39′,1″-cyclopropane]-9′-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-8-[2-(3,4-dichlorophenyl)ethyl]-12-ethoxy-20-(1-ethylpropyl)-N,N,3′,3′,4,19,22,26,32,35-decamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-32-cyclopropyl-8-[2-(3,4-dichlorophenyl)ethyl]-20-(2,2-dimethylpropyl)-12-ethoxy-27-(methoxymethyl)-N,N,3′,3′,4,19,22,26,35-nonamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38Z)-32-cyclopropyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-20-(2,2-dimethylpropyl)-12-ethoxy-N,N,3′,3′,4,19,22,26,35-nonamethyl-30-1[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-27-propyl-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclobutane]-23-carboxamide,
• (6'S,9'S,13'S,16'S,22'S,29'S,35'S,40a'S,Z)-16′-((S)-sec-butyl)-35′-(3-chloro-4-(trifluoromethyl)phenethyl)-13′-(methoxymethyl)-N,N,3,3,5′,8′,12′,18′,21′,31′-decamethyl-29′-(4-methylbenzyl)-1′,4′,7′,11′,14′,17′,20′,30′,33′,36′,41′-undecaoxo-6′-(pentan-3-yl)-1′,2′,4′,5′,6′,7′,8′,9′,10′,11′,12′,13′,14′,15′,16′,17′,18′,19′,20′,21′,22′,23′,26′,27′,29′,30′,31′,32′,33′,34′,35′,36′,40′,40a′-tetratriacontahydro-38′H-dispiro[cyclobutane-1,3′-[22,28]methanopyrrolo[1,2-j][1,4,7,10,13,16,19,23,26,29,32]undecaazacyclooctatriacontine-39′,1″-cyclopropane]-9′-carboxamide, and
• (2S,8S,12R,14S,20S,23S,27S,30S,36S,38E)-20-cyclopentyl-8-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-12-ethoxy-38-fluoro-27-isobutyl-N,N,4,19,22,26,32,35-octamethyl-30-[(1S)-1-methylpropyl]-3,6,9,15,18,21,25,28,31,34,42-undecaoxo-2-[[4-(trifluoromethyl)phenyl]methyl]spiro[1,4,7,10,16,19,22,26,29,32,35-undecazatricyclo[34.5.1.010,14]dotetracont-38-ene-17,1′-cyclopentane]-23-carboxamide, or salt thereof, or solvate thereof.